Metraipolis › archive › dc_eb72f4b43812

AOZORA study: 3-year interim analysis of safety and joint health in pediatric people with hemophilia A receiving emicizumab prophylaxis — Europe PMC PMID:41362697

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41362697
DOI
10.1016/j.rpth.2025.103228
License (as archived)
solo-consultazione
Archived
2026-11-09T04:33:18.984Z
SHA-256 of the archived text
f58a56736d5a0e6d4c95633e8dd6d6fd15e8b4792049c1a1041f6990e1160af8
Stable URL of this page
https://metraipolis.com/documento/dc_eb72f4b43812

How to cite

AOZORA study: 3-year interim analysis of safety and joint health in pediatric people with hemophilia A receiving emicizumab prophylaxis — Europe PMC PMID:41362697 — Europe PMC (en), https://europepmc.org/article/MED/41362697 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_eb72f4b43812 (Metraipolis archive dc_eb72f4b43812, sha256 f58a56736d5a0e6d4c95633e8dd6d6fd15e8b4792049c1a1041f6990e1160af8)
BibTeX
@misc{dceb72f4b43812,
  title = {AOZORA study: 3-year interim analysis of safety and joint health in pediatric people with hemophilia A receiving emicizumab prophylaxis — Europe PMC PMID:41362697},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41362697},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_eb72f4b43812; sha256 f58a56736d5a0e6d4c95633e8dd6d6fd15e8b4792049c1a1041f6990e1160af8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41362697. Agents can read the archived copy with the MCP tool read_document.